bamifylline has been researched along with tacrolimus in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barilli, A; Bonomini, S; Bussolati, O; Closs, EI; Dall'Asta, V; Gazzola, GC; Parolari, A; Sala, R; Simon, A; Tremoli, E; Visigalli, R | 1 |
1 other study(ies) available for bamifylline and tacrolimus
Article | Year |
---|---|
In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Cardiovascular Agents; Carrier Proteins; Caspase 3; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; E-Selectin; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; Immunoprecipitation; L-Lactate Dehydrogenase; Mechanistic Target of Rapamycin Complex 1; Microscopy, Confocal; Multiprotein Complexes; Necrosis; Nitric Oxide; Nitric Oxide Synthase Type III; Polymerase Chain Reaction; Protein Kinases; Proteins; Rapamycin-Insensitive Companion of mTOR Protein; Regulatory-Associated Protein of mTOR; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Stress Fibers; Tacrolimus; Theophylline; Time Factors; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2008 |